The Dip in Chewy Stock Could Be a Gift. Here's How It Could Set You Up for Life.

Autoship has grown from 73% of Chewy's sales in 2022 to 83% in 2025, driving gross margin expansion from 20% (2019) to 29% and EBITDA margin from -7% to 3%; management targets ~10% EBITDA long-term. Management is guiding ~8% sales growth for 2026 and the stock trades at ~17x forward earnings. New higher-margin initiatives (Chewy Vet Care with 18 clinics, advertising, Chewy Made private label, Chewy Pharmacy, Chewy+ membership) are highlighted as the next levers for margin expansion.

Analysis

Chewy's combination of recurring-subscription demand, first-party pet health touchpoints, and an owned fulfillment mesh creates a rare ability to both reduce customer acquisition churn and compress per-order fulfillment cost. That structural mix lets it reallocate margin potential away from low-margin branded food toward higher-margin dollars from pharmacy, vet services, advertising, memberships and private label, and it also increases bargaining leverage with national brands and distributors — expect branded suppliers to push for trade/promotional support or risk SKU rationalization in the channel.

Second-order winners include digital ad platforms and CPG suppliers that can prove ROI to Chewy’s audience (they get precision targeting plus purchase intent), while traditional brick-and-mortar players face a sustained unit-cost disadvantage on bulky categories. Conversely, local independent vet clinics and small specialty chains could see a two‑to‑three year squeeze on routine services as Chewy cross‑sells preventative care and pharmacy refills, forcing consolidation or price competition in regional markets.

Key execution risks are not macro but operational and regulatory: scaling owned clinics requires talent, licensure variability by state, and capex cadence that can delay profitability pacing; advertising revenue hinges on measurable campaign ROAS which can be volatile mid-cycle; and private‑label margins are sensitive to commodity feedstock swings. Watchable catalysts over the next 2–12 months are membership adoption velocity, ad ARPU trends, early CVC unit economics, and private‑label mix shift — these move the margin story from credible to probable.

The consensus is underweighting the asymmetric optionality of first‑party pet health data to become a platform for higher-margin services; the counterargument is that clinic and pharmacy execution is capital and time intensive and could compress near-term margins if growth comes faster than unit profitability improves. Position sizing should reflect that dichotomy: treat growth as multi-year with binary near‑term operational readouts that will re-rate sentiment fast.

Key Decisions for Investors

• Long CHWY equity (size 3–6% of active risk budget), horizon 6–12 months. Thesis: execution on membership + ad ARPU + private‑label mix drives 20–35% upside. Cut if any two consecutive quarters show negative ad ARPU or declining membership retention; initial stop -15% from entry.
• Pair trade: Long CHWY / Short WOOF (Petco) 1:1, horizon 6–12 months. Rationale: capture structural share shift to recurring e‑commerce + services while hedging broad pet‑retail cyclicality. Target relative outperformance 15–25%; risk if Petco executes higher‑margin services faster than expected.
• Options: Buy a 12‑month CHWY call (LEAP) and sell a higher‑strike call to create a debit call spread sized to 1–2% portfolio risk. This caps premium spend while keeping upside exposure to successful clinic/ad monetization prints; breakeven defined by net premium paid.
• Event hedge / monitoring: If upcoming quarterly prints miss ad ARPU or CVC EBITDA inflects negatively, buy put protection (3–6 month) sized ~50% of equity position to limit downside while management updates cadence on clinic rollouts.